Plain-English translation of NCT07193654 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Glioblastoma is an aggressive brain cancer that is very difficult to treat, especially when it has spread to the fluid-filled spaces in the brain or to the protective membranes around the brain and spinal cord. This trial is testing whether combining the standard treatment (surgery, radiation, and chemotherapy pills called temozolomide, known as the Stupp regimen) with thiotepa—a chemotherapy drug injected directly into the spinal fluid—can help fight the disease more effectively. The goal is to get more medication directly to where the cancer is spreading, which may improve survival.
The blood-brain barrier—a natural wall that protects the brain—makes it very hard for regular chemotherapy to reach cancer cells in the brain and spinal fluid. This medication injected directly into the spinal fluid is designed to bypass that barrier and attack cancer cells in these hard-to-reach areas, which could improve outcomes for patients with advanced glioblastoma.
You likely qualify if…
You likely don't qualify if…
You would receive the standard Stupp regimen (surgery if needed, radiation therapy, and chemotherapy pills) along with injections of thiotepa directly into your spinal fluid through lumbar puncture procedures. The trial will monitor how well the treatment works and how you tolerate it, with regular blood tests, imaging scans, and clinical assessments. The study is enrolling 38 patients and will follow your progress over time to see if this combination approach improves survival and disease control.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China